International Journal of Pediatrics drugs,” New England Journal of Medicine, vol. 360, pp. 1597– 1605, 2009. [43] S. L. Hans, “Prenatal drug exposure: behavioral functioning in late childhood and adolescence,” NIDA Research Monograph, vol. 164, pp. 261–276, 1996. [44] K. A. Kaltenbach, “Eﬀects of in-utero opiate exposure: new paradigms for old questions,” Drug and Alcohol Dependence, vol. 36, no. 2, pp. 83–87, 1994. [45] K. A. Kaltenbach, “Exposure to opiates: behavioral outcomes in preschool and school-age children,” NIDA Research Mono- graph, vol. 164, pp. 230–241, 1996. [46] B. M. Lester and L. L. Lagasse, “Children of addicted women,” Journal of Addictive Diseases, vol. 29, no. 2, pp. 259–276, 2010. [47] A. H. Schempf, “Illicit drug use and neonatal outcomes: a critical review,” Obstetrical and Gynecological Survey, vol. 62, no. 11, pp. 749–757, 2007. [48] K. B. Walhovd, V. Moe, K. Slinning et al., “Eﬀects of prenatal opiate exposure on brain development—a call for attention,” Nature Reviews Neuroscience, vol. 10, no. 5, p. 390, 2009. [49] R. W. Hunt, D. Tzioumi, E. Collins, and H. E. Jeﬀery, “Adverse neurodevelopmental outcome of infants exposed to opiate in- utero,” Early Human Development, vol. 84, no. 1, pp. 29–35, 2008. [50] K. Kaltenbach and L. P. Finnegan, “Developmental outcome of children born to methadone maintained women: a review of longitudinal studies,” Neurobehavioral Toxicology and Tera- tology, vol. 6, no. 4, pp. 271–275, 1984. [51] K. A. Kaltenbach and L. P. Finnegan, “Prenatal narcotic expo- sure: perinatal and developmental eﬀects,” Neurotoxicology, vol. 10, no. 3, pp. 597–604, 1989. [52] H. M. E. Belcher, B. K. Shapiro, M. Leppert et al., “Sequen- tial neuromotor examination in children with intrauterine cocaine/polydrug exposure,” Developmental Medicine and Child Neurology, vol. 41, no. 4, pp. 240–246, 1999. [53] K. Kaltenbach and L. P. Finnegan, “Neonatal abstinence syndrome, pharmacotherapy and developmental outcome,” Neurobehavioral Toxicology and Teratology, vol. 8, no. 4, pp. 353–355, 1986. [54] A. Van Baar, “Development of infants of drug dependent mothers,” Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 31, no. 6, pp. 911–920, 1990. [55] V. Moe, “Foster-placed and adopted children exposed in utero to opiates and other substances: prediction and outcome at four and a half years,” Journal of Developmental and Behavioral Pediatrics, vol. 23, no. 5, pp. 330–339, 2002. [56] A. Ornoy, J. Segal, R. Bar-Hamburger, and C. Greenbaum, “Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmen- tal factors,” Developmental Medicine and Child Neurology, vol. 43, no. 10, pp. 668–675, 2001. [57] J. L. Jacobson and S. W. Jacobson, “Prospective, longitudinal assessment of developmental neurotoxicity,” Environmental Health Perspectives, vol. 104, no. 2, pp. 275–283, 1996. [58] H. E. Jones, K. Kaltenbach, and K. E. O’Grady, “The com- plexity of examining developmental outcomes of children prenatally exposed to opiates. A response to the Hunt et al. Adverse neurodevelopmental outcome of infants exposed to opiates in-utero. Early Human Development (2008, 84, 29– 35),” Early Human Development, vol. 85, no. 4, pp. 271–272, 2009. [59] M. Levine, S. Walter, H. Lee, T. Haines, A. Holbrook, and V. Moyer, “Users’ guides to the medical literature—4. How to use an article about harm,” Journal of the American Medical Association, vol. 271, no. 20, pp. 1615–1619, 1994. 5 [60] R. Bunikowski, I. Grimmer, A. Heiser, B. Metze, A. Scha¨fer, and M. Obladen, “Neurodevelopmental outcome after prena- tal exposure to opiates,” European Journal of Pediatrics, vol. 157, no. 9, pp. 724–730, 1998. [61] D. D. Davis and D. I. Templer, “Neurobehavioral functioning in children exposed to narcotics in utero,” Addictive Behaviors, vol. 13, no. 3, pp. 275–283, 1988. [62] M. M. De Cubas and T. Field, “Children of methadone- dependent women: developmental outcomes,” American Jour- nal of Orthopsychiatry, vol. 63, no. 2, pp. 266–276, 1993. [63] X. Guo, J. W. Spencer, P. E. Suess, J. E. Hickey, W. E. Better, and R. I. Herning, “Cognitive brain potential alterations in boys exposed to opiates: in utero and lifestyle comparisons,” Addictive Behaviors, vol. 19, no. 4, pp. 429–441, 1994. [64] M. H. Lifschitz, G. S. Wilson, E. O’Brian Smith, and M. M. Desmond, “Factors aﬀecting head growth and intellectual function in children of drug addicts,” Pediatrics, vol. 75, no. 2, pp. 269–274, 1985. [65] B. M. Lester, E. Z. Tronick, L. LaGasse et al., “The maternal lifestyle study: eﬀects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants,” Pediatrics, vol. 110, no. 6 I, pp. 1182–1192, 2002. [66] D. S. Messinger, C. R. Bauer, A. Das et al., “The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age,” Pediatrics, vol. 113, no. 6 I, pp. 1677–1685, 2004. [67] N. Ebner, K. Rohrmeister, B. Winklbaur et al., “Management of neonatal abstinence syndrome in neonates born to opioid maintained women,” Drug and Alcohol Dependence, vol. 87, no. 2-3, pp. 131–138, 2007. [68] L. Jackson, A. Ting, S. Mckay, P. Galea, and C. Skeoch, “A randomized controlled trial of morphine versus phenobarbi- tone for neonatal abstinence syndrome,” Archives of Disease in Childhood, vol. 89, no. 4, pp. F300–F304, 2004. [69] K. T. Khoo, The eﬀectiveness of three treatment regimens used in the management of neonatal abstinence syndrome, Ph.D. thesis, University of Melbourne, 1995. [70] M. G. Coyle, A. Ferguson, L. LaGasse, J. Liu, and B. Lester, “Neurobehavioral eﬀects of treatment for opiate withdrawal,” Archives of Disease in Childhood, vol. 90, no. 1, pp. F73–F74, 2005. [71] M. G. Coyle, A. Ferguson, L. Lagasse, W. Oh, and B. Lester, “Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants,” Journal of Pediatrics, vol. 140, no. 5, pp. 561–564, 2002. [72] A. G. Agthe, G. R. Kim, K. B. Mathias et al., “Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial,” Pediatrics, vol. 123, no. 5, pp. e849–e856, 2009. [73] A. Esmaeili, A. K. Keinhorst, T. Schuster, F. Beske, R. Schlo¨sser, and C. Bastanier, “Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate,” Acta Paediatrica, vol. 99, no. 2, pp. 209–214, 2010. [74] J. B. Leikin, W. P. MacKendrick, G. E. Maloney et al., “Use of clonidine in the prevention and management of neonatal abstinence syndrome,” Clinical Toxicology, vol. 47, no. 6, pp. 551–555, 2009.